| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW ARTICLE |
1 From the Department of Food Science and Technology, University of California, Davis, CA (AMZ and JBG); the Nestlé Research Centre, Lausanne, Switzerland (JBG); and the Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA (AJS)
Nonalcoholic fatty liver disease (NAFLD) is a significant health problem and affects 70 million adults in the United States (30% of the adult population), and an estimated 20% of these individuals have the most severe form of NAFLD—nonalcoholic steatohepatitis (NASH). The mechanisms underlying disease development and progression are awaiting clarification. Insulin resistance and obesity-related inflammation, among other possible genetic, dietary, and lifestyle factors, are thought to play a key role. A program targeting gradual weight reduction and physical exercise continues to be the gold standard of treatment for all forms of NAFLD. Even though weight loss and dietary and lifestyle changes are recommended as primary treatment for fatty liver, little to no scientific evidence is available on diet and NAFLD. This article reviews the implications of current dietary approaches, including national guidelines and popular weight-loss diets, with a focus on determining the optimal diet to prescribe for NAFLD and NASH patients. The effects of macronutrient content (carbohydrate, fat, and protein ratios) and specific food components, such as soluble fiber, n–3 fatty acids, and fructose, are discussed. The premises, effects, barriers, and issues related to current dietary guidelines and specific diets are discussed, and the question, "Will it work for the pathogenesis of NAFLD and NASH? ", is addressed.
Key Words: Nonalcoholic fatty liver disease • NAFLD • nonalcoholic steatohepatitis • NASH • diet • weight loss
This article has been cited by other articles:
|
|
 |
|
  Y. Noguchi, J. D. Young, J. O. Aleman, M. E. Hansen, J. K. Kelleher, and G. Stephanopoulos Effect of Anaplerotic Fluxes and Amino Acid Availability on Hepatic Lipoapoptosis J. Biol. Chem., November 27, 2009; 284(48): 33425 - 33436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Livesey Fructose Ingestion: Dose-Dependent Responses in Health Research J. Nutr., June 1, 2009; 139(6): 1246S - 1252S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Schaefer, J. A. Gleason, and M. L. Dansinger Dietary Fructose and Glucose Differentially Affect Lipid and Glucose Homeostasis J. Nutr., June 1, 2009; 139(6): 1257S - 1262S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Erickson Nonalcoholic fatty liver disease J. Lipid Res., April 1, 2009; 50(Supplement): S412 - S416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Manco, G. Bottazzo, R. DeVito, M. Marcellini, G. Mingrone, and V. Nobili Nonalcoholic Fatty Liver Disease in Children J. Am. Coll. Nutr., December 1, 2008; 27(6): 667 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Livesey and R. Taylor Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1419 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chitturi Review: Treatment options for nonalcoholic fatty liver disease Therapeutic Advances in Gastroenterology, November 1, 2008; 1(3): 173 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 M. N. Feinglos and S. E. Totten Are You What You Eat, or How Much You Eat?: The Case of Type 2 Diabetes Mellitus Arch Intern Med, July 28, 2008; 168(14): 1485 - 1486. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Hwang, D. T. Stein, N. Barzilai, M.-H. Cui, J. Tonelli, P. Kishore, and M. Hawkins Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1663 - E1669. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
